A Registry for People With T-cell Lymphoma

Recruiting

• Conditions: Chronic Lymphoproliferative Disorder of NK Cells; Aggressive NK-cell Leukemia; Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder); Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood; Extranodal NK/T-cell Lymphoma, Nasal Type; Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract; Mycosis Fungoides; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; T-cell Lymphoma; Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
• Interventions: Other: Optional Blood Sample and Nail Sample

• Registration Number: NCT05978141
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-07-27
• Study First Submitted: 2023-07-28
• Study First Submitted QC: 2023-07-28
• Study First Posted: 2023-08-07
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-16
• Last Update Posted: 2025-05-21
• Primary Completion: 2030-07-27
• Study Completion: 2030-07-27

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Written informed consent

• Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.

• Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

  • T-cell prolymphocytic leukemia
  • T-cell large granular lymphocytic leukemia
  • Chronic lymphoproliferative disorder of NK cells
  • Aggressive NK-cell leukemia
  • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • Chronic active EBV infection of T- and NK-cell type, systemic form
  • Hydroa vacciniforme-like lymphoproliferative disorder
  • Adult T-cell leukemia/lymphoma
  • Extranodal NK/T-cell lymphoma, nasal type
  • Enteropathy-associated T-cell lymphoma
  • Monomorphic epitheliotropic intestinal T-cell lymphoma
  • Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • Sézary syndrome
  • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • Primary cutaneous Gamma-Delta T-cell lymphoma
  • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • Peripheral T-cell lymphoma, not otherwise specified
  • Angioimmunoblastic T-cell lymphoma
  • Follicular T-cell lymphoma
  • Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic large cell lymphoma, ALK-positive
  • Anaplastic large cell lymphoma, ALK-negative
  • Breast-implant associated anaplastic large cell lymphoma.

• NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion Criteria

• Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
• Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants with T-Cell Lymphoma	Optional Blood Sample and Nail Sample	Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma

Primary Outcome Measures

Name	Time	Method
Number of participants populating the T-cell Lymphoma Master Repository/TCLMR	10 years	To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.

Trial Locations

Locations (26)

Dana Farber Cancer Institute (Data Collection Only); 🇺🇸 Boston, Massachusetts, United States

University of Miami (Data Collection Only); 🇺🇸 Miami, Florida, United States

University of Nebraska (Data collection only); 🇺🇸 Omaha, Nebraska, United States

Memorial Sloan Kettering at Basking Ridge (All protocol activities); 🇺🇸 Basking Ridge, New Jersey, United States

City of Hope Cancer Center (Data collection only); 🇺🇸 Duarte, California, United States

University of Colorado (Data Collection Only); 🇺🇸 Aurora, Colorado, United States

Mayo Clinic (Data Collection Only); 🇺🇸 Rochester, Minnesota, United States

Northwestern Medicine (Data Collection); 🇺🇸 Chicago, Illinois, United States

Yale University (Data Collection Only); 🇺🇸 New Haven, Connecticut, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities); 🇺🇸 New York, New York, United States

University of Pennsylvania (Data Collection Only); 🇺🇸 Philadelphia, Pennsylvania, United States

Memorial Sloan Kettering Monmouth (All protocol activities); 🇺🇸 Middletown, New Jersey, United States

Weill Cornell Medical Center (Data Collection Only); 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Nassau (All protocol activities); 🇺🇸 Uniondale, New York, United States

MD Anderson Cancer Center (Data Collection Only); 🇺🇸 Houston, Texas, United States

Stanford University Medical Center (Data collection only); 🇺🇸 Stanford, California, United States

University of California San Francisco (Data collection only); 🇺🇸 San Francisco, California, United States

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only); 🇺🇸 San Diego, California, United States

Emory University (Data Collection Only); 🇺🇸 Atlanta, Georgia, United States

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities); 🇺🇸 Commack, New York, United States

Moffitt Cancer Center (Data Collection Only); 🇺🇸 Tampa, Florida, United States

Washington University (Data Collection Only); 🇺🇸 Saint Louis, Missouri, United States

Massachusetts General Hospital (Data Collection Only); 🇺🇸 Boston, Massachusetts, United States

Ohio State University (Data Collection Only); 🇺🇸 Columbus, Ohio, United States

Thomas Jefferson University Hospital (Data collection only); 🇺🇸 Philadelphia, Pennsylvania, United States

Memorial Sloan Kettering Westchester (All protocol activities); 🇺🇸 Harrison, New York, United States